The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early combination with mycophenolate mofetil for immune-related hepatitis in patients with solid tumors treated with immune checkpoint inhibitors.
 
Yukiko Shimoda Igawa
No Relationships to Disclose
 
Tatsuya Yoshida
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD Oncology; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai/Roche; Lilly Japan; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Yuri Yoshinami
No Relationships to Disclose
 
Yukiko Hibino
No Relationships to Disclose
 
Takamichi Arima
No Relationships to Disclose
 
Jun Sato
No Relationships to Disclose
 
Yuta Maruki
No Relationships to Disclose
 
Hirokazu Shoji
Research Funding - Amgen (Inst); Astellas Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Kenjiro Namikawa
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - MSD; Novartis
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Kazuki Sudo
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Janssen; MSD; Nihon Medi-Physics; Pfizer
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Merck; NanoCarrier; Pfizer; PRA Health Sciences; Takeda
 
Yoshitaka Honma
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Lilly; Merck Serono; MSD; Novartis; Nutrisystem; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Consulting or Advisory Role - Eisai; Janssen; Rakuten Medical Japan
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Lilly; Merck Serono; MSD; Novartis; Nutrisystem; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Adlai Nortye; Astellas Pharma; AstraZeneca; Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma; Genmab; GlaxoSmithKline; Janssen; Maruho; Merck Serono; MSD; Novartis; Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical Japan (Inst); Taiho Pharmaceutical
 
Hironobu Hashimoto
No Relationships to Disclose
 
Naoya Yamazaki
Consulting or Advisory Role - Incyte; Maruho; Ono Pharmaceutical; Otsuka
Speakers' Bureau - Bristol-Myers Squibb Japan; Maruho; MSD; Novartis; Ono Pharmaceutical; Sun Pharma
Research Funding - Astellas Amgen BioPharama (Inst); Bristol-Myers Squibb Japan (Inst); GlaxoSmithKline; Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Takara Bio (Inst)
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Kyowa Kirin International; Myriad Genetics; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Dainippon Sumitomo Pharma; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience; Eisai (Inst); Incyte; Syneos Health/Immunocore (Inst); Sysmex (Inst)
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Henlius; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Rakuten Medical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Yuichiro Ohe
Leadership - JCOG; JSMO
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; PharmaMar; PharmaMar; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)